Get started
Author

Andrea Hernández Rojas

Observed names: A. Hernandez Rojas, Andrea Hernandez Rojas
Institution: Zymeworks (Canada)
Observed institution: Zymeworks (Canada)
ORCID: 0000-0002-0278-9434
Observed ORCID: 0000-0002-0278-9434
OpenAlex ID: A5056200860
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
2023 · Nina E. Weisser, Mario Sanches, et al. · Nature Communications · 209
PDF
Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates
2024 · Mark E. Petersen, Michael G. Brant, et al. · Molecular Cancer Therapeutics · 30
PDF
Abstract 2633: Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
2023 · Stuart D. Barnscher, Andrea Hernández Rojas, et al. · Cancer Research · 14
Abstract 2658: ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Laurence Madera, Andrea Hernández Rojas, et al. · Cancer Research · 6
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
2023 · Mark E. Petersen, Michael G. Brant, et al. · Journal of Medicinal Chemistry · 5
Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Sam Lawn, Andrea Hernandez Rojas, et al. · Cancer Research · 3
Abstract 1533: ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Andrea Hernandez Rojas, Jodi Wong, et al. · Cancer Research · 3
Abstract 2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
2024 · Stuart D. Barnscher, Dunja Urosev, et al. · Cancer Research · 2
ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al. · Clinical Cancer Research · 1
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In Vivo
2026 · Andrea Hernández Rojas, Jodi Wong, et al. · Bioconjugate Chemistry · 1
177 (PB165): ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models
2024 · L. Madera, A. Wu, et al. · European Journal of Cancer · 1
Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications
2024 · Sam Lawn, Andrea Hernandez Rojas, et al. · Cancer Research · 1
Supplementary Figure S1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Data from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S10 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S7 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S12 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S9 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S6 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S13 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S4 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Works count: 54
Citation count: 276
H-index: 5
I10-index: 3
Year
Topic
Type